Myofascial pain syndrome
diseaseOn this page
Summary
Myofascial pain syndrome (MONDO:0006862) is a disease and 151 clinical trials. Top therapeutic interventions include lidocaine, baclofen, and botulinum toxin type a. A subtype of myopathy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 151
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | myofascial pain syndrome |
| Mondo ID | MONDO:0006862 |
| EFO | EFO:1001054 |
| MeSH | D009209 |
| DOID | DOID:431 |
| SNOMED CT | 24693007 |
| UMLS | C0027073 |
| MedGen | 6496 |
| GARD | 0024491 |
| MedDRA | 10048780 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of myopathy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › muscle tissue disorder › skeletal muscle disorder › myopathy › myofascial pain syndrome
Related subtypes (31): polyglucosan body myopathy, muscular atrophy, myopathy of extraocular muscle, acute quadriplegic myopathy, myopathy with abnormal lipid metabolism, proximal myopathy with focal depletion of mitochondria, Brody myopathy, rippling muscle disease, myopathy due to myoadenylate deaminase deficiency, proximal myopathy with extrapyramidal signs, intermediate nemaline myopathy, hereditary inclusion-body myopathy, hereditary continuous muscle fiber activity, congenital myopathy, muscular dystrophy, metabolic myopathy, myositis disease, collagen 6-related myopathy, myopathy caused by variation in CRPPA, drug-induced myopathy, myopathy caused by variation in FKRP, myopathy caused by variation in FKTN, myopathy caused by variation in POMGNT1, myopathy caused by variation in POMGNT2, myopathy caused by variation in POMT1, myopathy caused by variation in POMT2, myopathy caused by variation in GMPPB, FHL1-related myopathy, myopathy, sarcoplasmic body, myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis 2, myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis
Subtypes (1): temporomandibular joint dysfunction syndrome
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Onabotulinumtoxina | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Capsaicin, Lidocaine, Tetracaine.
Clinical trials & evidence
Clinical trials
Clinical trials: 151.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 129 |
| PHASE2 | 8 |
| PHASE3 | 6 |
| PHASE4 | 5 |
| PHASE1/PHASE2 | 1 |
| PHASE1 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07082972 | PHASE4 | RECRUITING | EMG-Based Evaluation of Occlusal Splint and Masseter Botox Effects on Head and Neck Muscles |
| NCT00241215 | PHASE4 | COMPLETED | Study to Evaluate the Efficacy of Botulinum Toxin Serotype A Injections for Cervicobrachial Myofascial Syndrome |
| NCT00272532 | PHASE4 | COMPLETED | EMINEM: Efficacy of Muscoril In NEck Myofascial Syndromes |
| NCT01250184 | PHASE4 | COMPLETED | Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy. |
| NCT02120261 | PHASE4 | TERMINATED | Using Saline for Myofascial Pain Syndromes (USAMPS) |
| NCT00246142 | PHASE3 | COMPLETED | A Study of the Combination of Electrical Stimulation and Dysport® in Myofascial Pain Syndrome. |
| NCT02436096 | PHASE3 | COMPLETED | A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia |
| NCT02829814 | PHASE3 | TERMINATED | Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia |
| NCT03223298 | PHASE3 | COMPLETED | Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles |
| NCT04286880 | PHASE3 | UNKNOWN | Comparative Efficacy of PRP and Dry Needling in Management of Trigger Points in Masseter Muscle in MPS Patients |
| NCT04703803 | PHASE3 | COMPLETED | Efficacy of Myofascial Pain Syndrome Treatment in Patients With Cancer in Palliative Care |
| NCT06975813 | PHASE2 | NOT_YET_RECRUITING | Magnesium Sulfate and Trigger Points |
| NCT00134810 | PHASE2 | COMPLETED | Study to Assess the Efficacy and Safety of Dysport® in Upper Back Myofascial Pain Syndrome |
| NCT00149240 | PHASE2 | COMPLETED | Botulinum Toxin Type A (Dysport) Associated With Rehabilitation Treatment in Patients With Primary Myofascial Pain Syndrome |
| NCT00795106 | PHASE2 | WITHDRAWN | Trial to Evaluate the Efficacy of Topical Capsaicin to Reduce Pain and Improve Health-related Quality of Life in Adults With Chronic Myofascial Neck Pain |
| NCT01106989 | PHASE2 | COMPLETED | Study Evaluating Heated Lidocaine/Tetracaine Patch in Patients With Pain Associated With Myofascial Trigger Points |
| NCT01174667 | PHASE1/PHASE2 | UNKNOWN | Massage of the Low Back Muscles Assessed With Ultrasound Scanning |
| NCT01418170 | PHASE2 | COMPLETED | Dose Response Effects of Cervical Spinal Manipulative Therapy (SMT) on Pressure Sensitivity of Myofascial Trigger Points |
| NCT04267315 | PHASE2 | UNKNOWN | Trigger Point Injections for Post-Mastectomy Pain Syndrome |
| NCT04417101 | PHASE2 | UNKNOWN | Chinese Herbal Medicine for Dialysis-related Myofascial Pain: Study Protocol for A Pilot Randomized Study |
| NCT02173405 | PHASE1 | COMPLETED | Injection With OnabotulinumtoxinA (Botox) for the Treatment of Chronic Pelvic Pain |
| NCT06013644 | EARLY_PHASE1 | UNKNOWN | Acupuncture, Dry Needle and Botox Injection in Management of Patient With Myofascial Pain Dysfunction Syndrome |
| NCT06444035 | Not specified | ENROLLING_BY_INVITATION | Extended Therapeutic Effect of 35kDa Hyaluronan Fragment Injection in Patients With Chronic Pain Caused by Myofascial Pain Syndrome |
| NCT06538727 | Not specified | NOT_YET_RECRUITING | Pilot MRI Study on Osteopathic Manipulation for Myofascial Pain Syndrome |
| NCT06845475 | Not specified | NOT_YET_RECRUITING | Effect of Shock Wave Therapy on Myofascial Pain Syndrome in Adolescent Athletes |
| NCT06982456 | Not specified | ENROLLING_BY_INVITATION | Manual Therapy Techniques for Cervical Pain: Algometric Evaluation |
| NCT07045324 | Not specified | ACTIVE_NOT_RECRUITING | Effect of Vagus Nerve Stimulation on Trapezius Trigger Point |
| NCT07119255 | Not specified | RECRUITING | Effectiveness of PRP Pharmacopuncture for Chronic Neck Pain in Cervical Myofascial Syndrome of the Upper Trapezius |
| NCT07130279 | Not specified | NOT_YET_RECRUITING | Post-Isometric Relaxation in Temporomandibular Disorders |
| NCT07352787 | Not specified | NOT_YET_RECRUITING | High-Intensity Laser Therapy for Trapezius Myofascial Pain (HILT-TRAP Study) |
| NCT07395154 | Not specified | NOT_YET_RECRUITING | Comparison of Integrated Neuromuscular Inhibition Technique (INIT) and Active Release Technique (ART) in Patients With Upper Trapezius Trigger Points |
| NCT07494162 | Not specified | NOT_YET_RECRUITING | Imaging Metabolic and Perfusion Changes in Acupuncture Therapy for Myofascial Pain Syndrome |
| NCT07511751 | Not specified | RECRUITING | COMPARISON OF THREE TREATMENT MODALITIES IN MYOFASCIAL PAIN SYNDROME |
| NCT07525921 | Not specified | RECRUITING | Immediate Effect of Dry Needling on Calf Muscles Pain Pressure Threshold,Sprint Speed and Functional Performance in Amateur Football Player |
| NCT07573527 | Not specified | NOT_YET_RECRUITING | Effectiveness of Tele-Rehabilitation in Managing Rhomboid Trigger Points in Patients With Myofascial Pain Syndrome |
| NCT00635037 | Not specified | COMPLETED | Myofascial Pain:Acupuncture Versus Trigger Point Injection Combined With Dipyrone and Cyclobenzaprine |
| NCT01032863 | Not specified | COMPLETED | Association Between Hypermobility and Chronic Musculoskeletal Pain |
| NCT01167036 | Not specified | COMPLETED | Effectiveness of a Massage Instrument Compared to Placebo for Upper Trapezius Muscle Pain |
| NCT01381380 | Not specified | COMPLETED | Manual Therapy Treatment for Myofascial Pain |
| NCT01710735 | Not specified | COMPLETED | Skeletal Muscle Contractility, Self-reported Pain and Tissue Sensitivity in Females With Neck/Shoulder Pain and Trapezius MFTrPs |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| LIDOCAINE | 4 | 5 |
| BACLOFEN | 4 | 1 |
| BOTULINUM TOXIN TYPE A | 4 | 1 |
| CAPSAICIN | 4 | 1 |
| MEPIVACAINE HYDROCHLORIDE | 4 | 1 |
| ONABOTULINUMTOXINA | 4 | 1 |
| SALICYLIC ACID | 4 | 1 |
| TRIAMCINOLONE ACETONIDE | 4 | 1 |
| OZONE | 3 | 3 |
| THIOCOLCHICOSIDE | 3 | 1 |
| ZUCAPSAICIN | 3 | 1 |
| CHEMBL423707 | 0 | 1 |
| CHEMBL4090631 | 0 | 1 |